Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

Ulrich Ebensperger

Financial Analyst
share with twitter share with LinkedIn share with facebook
share via e-mail

A trend reversal can be anticipated

Strategy published on 10/24/2016 | 07:03
long trade
Stop-loss triggered
Entry price : 75.2CHF | Target : 80CHF | Stop-loss : 73.8CHF | Potential : 6.38%
Shares in Novartis AG reflect an interesting technical chart pattern allowing for a bet on a reversal of the medium term trend.
Investors have an opportunity to buy the stock and target the CHF 80.
  • For a short-term investment strategy, the company has poor fundamentals.

  • The share is getting closer to its long-term support in weekly data, at CHF 68.5, which offers good timing for buyers.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is one of the best yield companies with high dividend expectations.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's enterprise value to sales, at 3.96 times its current sales, is high.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 52 099 M
EBIT 2018 13 607 M
Net income 2018 8 905 M
Debt 2018 17 967 M
Yield 2018 3,69%
P/E ratio 2018 20,64
P/E ratio 2019 18,92
EV / Sales 2018 4,46x
EV / Sales 2019 4,26x
Capitalization 215 B
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Duration : Period : Week
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders